JASMONATE / CANCER RESEARCH READING ROOM
A plant stress signal at the edge of a cancer-biology question. We are fascinated by the possibility and committed to following the experiment wherever it leads.
The selected papers below study cells, isolated biological systems or animals. They do not establish that jasmonates prevent or treat cancer in people. We provide educational reading tools, with the primary sources and their limits in view. Read our research standards and corrections process.
THE OCTOBER READING PATH
Four original articles connect the experimental finding to its model, its primary source and the work still needed.
A curious, careful tour of breast cancer cell experiments, plant-derived bioactivities and the gap between a laboratory finding and a patient benefit.
Follow the evidence02 / 5 MIN READBreast Cancer Awareness Month is a reason to make the boundaries of experimental jasmonate research easier to see.
Follow the evidence03 / 5 MIN READWhy researchers study methyl jasmonate at the interface of cell energy and cell death, and what a mechanism can and cannot establish.
Follow the evidence04 / 5 MIN READAn evidence map for keeping cell, ex vivo and animal findings attached to the questions they can answer.
Follow the evidenceKEEP THE MODEL IN THE SENTENCE
A compelling cell result is a reason to investigate. Its evidence stage is part of what it means.
Binding assays, isolated mitochondria and cultured cells help researchers test specific interactions and measured responses.
BoundaryThey do not establish effects in a whole person. Cell identity, material, comparator and assay matter.
Cells obtained from people and examined outside the body remain ex vivo evidence. Animal experiments add physiology within a defined model.
BoundaryNeither is automatically an interventional human study. Species, immune status, tumor model and endpoint constrain translation.
Claims about people require research addressing human safety, exposure and clinically meaningful outcomes.
BoundaryThe selected primary papers in this reading room do not establish cancer prevention or treatment benefit in people.
PRIMARY PAPERS / SELECTED READING
Read the original record. These seven anchors introduce experimental mechanisms, breast-model questions and a crucial model-identity case. This is a selected reading list, not a systematic review.
How does plant JA perception shape mixtures with bioactivity in breast cancer cell models?
Direct MeJA and treated plant material are different exposures. This does not demonstrate a benefit from eating plants or a treatment for people.
Can a proposed interaction at hexokinase and mitochondria help explain susceptibility in the experimental systems?
A molecular target is a research hypothesis to test. It does not establish a human therapeutic window, delivery or patient benefit.
Can isolated cancer-cell mitochondria respond directly, including those from CLL samples examined outside the body?
Patient-derived cells outside the body are not evidence that patients received jasmonates or benefited from them.
How do metabolic, mitochondrial and tumor-growth measurements relate within the experimental models?
BEL-7402, SMMC-7721 and LO2/HL-7702 have published authentication concerns [A01]. The exact stocks used here were not independently verified in this preparation. Tissue and normal-liver selectivity claims require caution. The HCC-LM3 mouse model is separate from those named-line concerns. Immunodeficient xenografts do not establish human safety or benefit.
Were the cells carrying the reported tissue label?
Independent-stock authentication findings require caution with tissue and normal-liver comparator labels in S06. They do not determine the exact stocks used by Li and colleagues or resolve the separate HCC-LM3 mouse experiment.
What did the early experiments find when JA and methyl jasmonate were examined separately?
The material and model must stay attached to each result. The animal experiment concerns lymphoma, not a human breast cancer study.
What happens to an older breast-labelled claim when the cell line is authenticated as melanoma-derived?
Model identity changes tissue interpretation. It does not erase measurements in that line or invalidate findings separately obtained in other models.
Primary abstracts or accessible full texts were checked on October 5, 2026. The paid reader's source registry identifies access limits, including an unresolved wording conflict in a 2024 MCF-7 abstract. Linked publications retain their own rights and do not endorse this site.
KEEP A RECORD WORTH REVISITING
The public articles and primary links stay free. These original downloads help you organize the reading, trace a claim and return to the unanswered question.
A 17-page original guide to eight selected jasmonate cancer studies, with an evidence map, source links and an editable claim worksheet.
A 12-page research reading journal with ten reusable sheets, fifty fillable fields and editable CSV companions.
Research-reading aids for personal or internal use. No patient records, treatment plans, dosing, chemical products, accreditation or clinical outcome promise. The two products are separate from the garden bundle.
AN INDEPENDENT READING ROOM
If these pages are useful, you can support the continuation of this educational website. Choose your amount and receive one thank-you PDF from Nick.
Voluntary creator support, including $0. No charity affiliation, donation receipt, clinical trial funding or promise of laboratory research funding.
KEEP READING
Understand the difference between eliciting useful plant compounds and testing methyl jasmonate directly on cancer cells.
Understand the experimental hexokinase-mitochondria finding and the evidence still needed before clinical translation.
A careful explanation of p53-related lymphoma experiments, experimental resistance and the limits of laboratory models.
What a cervical cancer cell-line experiment measured, and why cell selectivity is not the same as safety in patients.
